2.80
-0.05 (-1.75%)
| Penutupan Terdahulu | 2.85 |
| Buka | 2.64 |
| Jumlah Dagangan | 75,924 |
| Purata Dagangan (3B) | 85,303 |
| Modal Pasaran | 41,993,012 |
| Harga / Jualan (P/S) | 256.05 |
| Harga / Buku (P/B) | 3.59 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -37,468.63% |
| EPS Cair (TTM) | 3.38 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -51.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -19.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 26.43% |
| Nisbah Semasa (MRQ) | 2.45 |
| Aliran Tunai Operasi (OCF TTM) | -19.88 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -11.33 M |
| Pulangan Atas Aset (ROA TTM) | -135.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -485.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Serina Therapeutics, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 63.85% |
| % Dimiliki oleh Institusi | 3.37% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Waverly Advisors, Llc | 31 Mar 2026 | 67,492 |
| Keel Point, Llc | 31 Mar 2026 | 21,508 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |